Search research articles
Contact Us
Filters
Showing results (291-300 of 377) with videos related to
Page
of 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2021
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial
Sibylle Loibl, Frederik Marmé, Miguel Martin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer
Matteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
Geburtshilfe Und Frauenheilkunde
|
June 17, 2024
Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast Cancer
Rachel Würstlein, Hans-Christian Kolberg, Andreas D Hartkopf, et al.
Breast Cancer Research and Treatment
|
November 21, 2022
Return of individual genomic research results within the PRAEGNANT multicenter registry study
Hanna Huebner, Matthias Ruebner, Christian Kurbacher, et al.
Breast Care (Basel, Switzerland)
|
January 14, 2014
13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013)
Michael Untch, Bernd Gerber, Nadia Harbeck, et al.
The Lancet. Oncology
|
August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 24, 2014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers
Carsten Denkert, Gunter von Minckwitz, Jan C Brase, et al.
Geburtshilfe Und Frauenheilkunde
|
November 11, 2020
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
Elena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 20, 2021
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
Sonia L Villegas, Valentina Nekljudova, Nicole Pfarr, et al.
Page
of 38
Search research articles
Search
Showing results (291-300 of 377) with videos related to
Sort By:
Page
of 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2021
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial
Sibylle Loibl, Frederik Marmé, Miguel Martin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer
Matteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
Geburtshilfe Und Frauenheilkunde
|
June 17, 2024
Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast Cancer
Rachel Würstlein, Hans-Christian Kolberg, Andreas D Hartkopf, et al.
Breast Cancer Research and Treatment
|
November 21, 2022
Return of individual genomic research results within the PRAEGNANT multicenter registry study
Hanna Huebner, Matthias Ruebner, Christian Kurbacher, et al.
Breast Care (Basel, Switzerland)
|
January 14, 2014
13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013)
Michael Untch, Bernd Gerber, Nadia Harbeck, et al.
The Lancet. Oncology
|
August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 24, 2014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers
Carsten Denkert, Gunter von Minckwitz, Jan C Brase, et al.
Geburtshilfe Und Frauenheilkunde
|
November 11, 2020
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
Elena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 20, 2021
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
Sonia L Villegas, Valentina Nekljudova, Nicole Pfarr, et al.
Page
of 38